2025年4月22日 星期二
首页        期刊介绍        编委会        投稿指南        期刊订阅        广告合作        联系我们        English
河北医学  2021, Vol. 27 Issue (10): 1598-1602    DOI: 10.3969/j.issn.1006-6233.2021.10.003
  论著 本期目录 | 过刊浏览 | 高级检索 |
转录因子EZH2和RUNX3在骨巨细胞瘤中的表达及与复发的关系研究
李铁军, 文华军, 郑铁钢, 张朋, 张正孟, 王继孟
中国人民解放军陆军第八十一集团军医院骨科, 河北 张家口 075000
Expression of Transcription Factors EZH2 and RUNX3 in Giant Cell Tumor of Bone and Their Relationship with Recurrence
LI Tiejun, WEN Huajun, ZHENG Tiegang, et al
The Hospital of the 81st Group Army of PLA, Hebei Zhangjiakou 075000, China
全文: PDF (1896 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 目的:探讨zeste基因增强子同源物2(EZH2)和人类RUNT相关转录因子3(RUNX3)在骨巨细胞瘤中的表达,及与骨巨细胞瘤复发的关系。方法:选取2013年10月至2018年1月在本院经病理组织检查确诊为骨巨细胞瘤并接受手术治疗者53例为研究对象,术中收集骨巨细胞瘤患者瘤组织以及瘤旁组织(距瘤组织>3cm),采用免疫组织化学法检测EZH2和RUNX3的表达,分析其与患者临床病理特征的关系;采用Spearman进行相关性分析;术后随访36个月,比较复发组与未复发组EZH2和RUNX3的表达情况。结果:骨巨细胞瘤瘤组织EZH2阳性表达率(69.81%)高于瘤旁组织(15.09%)(P<0.05),RUNX3阳性表达率(32.08%)低于瘤旁组织(86.79%)(P<0.05);瘤组织EZH2、RUNX3表达与肿瘤直径、影像学分级、病理学分级、组织浸润程度均有关(P<0.05);Spearman相关性分析结果显示,骨巨细胞瘤瘤组织中EZH2、RUNX3表达呈负相关(r=-0.544,P<0.05);复发组EZH2阳性表达率(93.33%)高于未复发组(60.53%)(P<0.05),RUNX3阳性表达率(0.00%)低于未复发组(44.74%)(P<0.05)。结论:骨巨细胞瘤瘤组织中EZH2为高表达,RUNX3为低表达,且与患者临床病理特征密切相关,EZH2、RUNX3表达呈负相关,EZH2可能抑制RUNX3表达,EZH2、RUNX3可能用于骨巨细胞瘤的病情及预后评估。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
关键词 zeste基因增强子同源物2人类RUNT相关转录因子3骨巨细胞瘤    
AbstractObjective: To investigate the expression of zeste homolog 2 (EZH2) and human RUNT-related transcription factor 3 (RUNX3) in giant cell tumor of bone and its relationship with recurrence of giant cell tumor of bone. Methods: Fifty-three patients who were diagnosed with giant cell tumor of bone and were treated by surgical examination in our hospital from October 2013 to January 2018 were selected as the research subjects, and the tumor tissues and adjacent tissues (> 3 cm from the tumor tissue) of patients with giant cell tumor of bone were collected during surgery, the expressions of EZH2 and RUNX3 were detected by immunohistochemistry, and their relationships with the clinicopathological characteristics of patients were analyzed; Spearman was used for correlation analysis; and after 36 months follow-up, the expressions of EZH2 and RUNX3 were compared between the relapse group and the non-relapse group. Results: The positive expression rate of EZH2 (69.81%) in giant cell tumor of bone was higher than that in adjacent tissues (15.09%) (P<0.05), and the positive expression rate of RUNX3 (32.08%) was lower than that in adjacent tissues (86.79%) (P<0.05); the expressions of EZH2 and RUNX3 in the tumor tissues were related to tumor diameter, imaging grade, pathological grade and degree of infiltration (P<0.05); Spearman correlation analysis showed that the expressions of EZH2 and RUNX3 were negatively correlated in giant bone tumor tissue (r = -0.544, P<0.05); the positive expression rate of EZH2 in recurrent group (93.33%) was higher than that in non-recurrent group (60.53%) (P<0.05), and the positive expression rate of RUNX3 in recurrent group (0.00%) was lower than that in non-recurrent group (44.74%) (P<0.05). Conclusion: EZH2 is highly expressed in giant cell tumor of bone, and RUNX3 is lowly expressed, which is closely related to the clinicopathological characteristics of patients. The expressions of EZH2 and RUNX3 are negatively correlated, EZH2 may inhibit the expression of RUNX3, and EZH2 and RUNX3 may be used for the evaluations of the disease and prognosis of giant cell tumor of bone.
Key wordsEnhancer of zeste homolog 2    Human RUNT-related transcription factor 3    Giant cell tumor of bone
    
基金资助:河北省医学科学研究课题计划项目,(编号:20191797)
通讯作者: 郑铁钢   
引用本文:   
李铁军, 文华军, 郑铁钢, 张朋, 张正孟, 王继孟. 转录因子EZH2和RUNX3在骨巨细胞瘤中的表达及与复发的关系研究[J]. 河北医学, 2021, 27(10): 1598-1602.
LI Tiejun, WEN Huajun, ZHENG Tiegang, et al. Expression of Transcription Factors EZH2 and RUNX3 in Giant Cell Tumor of Bone and Their Relationship with Recurrence. HeBei Med, 2021, 27(10): 1598-1602.
链接本文:  
http://www.hbyxzzs.cn/CN/10.3969/j.issn.1006-6233.2021.10.003     或     http://www.hbyxzzs.cn/CN/Y2021/V27/I10/1598
冀ICP备2025106803号    冀公网安备13080202000786号
版权所有 © 2016 《河北医学》杂志社
本系统由北京玛格泰克科技发展有限公司设计开发